Pharmacokinetics of cefiderocol in a patient with carbapenem‐resistant Acinetobacter baumannii ventriculitis: A case report
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025-01 · 45 (1) · 66-69
DOI: 10.1002/phar.4632 ↗At a glance
Fallbericht in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, published online on 2024-12-04. Written by Natalie A Finch and 5 co-authors. Institution: Department of Pharmacy, Houston Methodist Hospital, Houston, Texas, USA. Major MEDLINE topics: Acinetobacter baumannii, Acinetobacter Infections, Anti-Bacterial Agents, Cephalosporins. Cited 10 times so far (Crossref); 5 references. The full text is freely available in PubMed Central. Funded by: NIAID NIH HHS, NIH HHS, National Institutes of Health.
Abstract (original language)
Objective
Cefiderocol is a novel antibiotic used to treat multidrug‐resistant bacterial infections. However, there is limited data on its effectiveness for ventriculitis. The objective of this study was to evaluate cefiderocol concentrations in both serum and cerebrospinal fluid (CSF) during the treatment of ventriculitis.
Method
A 54‐year‐old patient with carbapenem‐resistant Acinetobacter baumannii ventriculitis was given cefiderocol intravenously 2 g every 6 h (each dose administered over 3 h). Serial samples were obtained over a dosing interval at steady state, and cefiderocol concentrations in serum and CSF were assayed by liquid chromatography–tandem mass spectrometry (LC–MS/MS). Cefiderocol serum concentration‐time profile was characterized by a one‐compartment model with zero‐order input. Penetration into CSF was estimated as the CSF AUC/unbound serum AUC ratio.
Results
Observed total serum concentrations ranged between 24.6 and 76.7 mg/L, while CSF concentrations were approximately 10.0 mg/L. The AUC 0–6 of the free drug in serum and CSF were 181.6 and 60.2 mg h/L, respectively.
Conclusion
We observed minimal fluctuation of cefiderocol concentrations in CSF, questioning the conventional reliance on CSF/serum area under the curve (AUC) ratio as a measure of CNS penetration. Our experience suggests that a single CSF concentration (random or trough) could be directly compared to the minimum inhibitory concentration, offering a potentially simpler approach to evaluate dosing adequacy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy, Houston Methodist Hospital, Houston, Texas, USA.
- Division of Infectious Diseases, Department of Internal Medicine, Houston Methodist Hospital, Houston, Texas, USA.
- Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA.
ORCID profiles: Vincent H Tam
Funding
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
Cite
APA
Finch, N. A., Granillo, A., Pouya, N., Bhimraj, A., Miller, W. R., & Tam, V. H. (2025). Pharmacokinetics of cefiderocol in a patient with carbapenem‐resistant Acinetobacter baumannii ventriculitis: A case report. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 45(1), 66-69. https://doi.org/10.1002/phar.4632
Vancouver
Finch NA, Granillo A, Pouya N, Bhimraj A, Miller WR, Tam VH. Pharmacokinetics of cefiderocol in a patient with carbapenem‐resistant Acinetobacter baumannii ventriculitis: A case report. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025;45(1):66-69. doi:10.1002/phar.4632
BibTeX
@article{Finch2025,
author = {Finch, Natalie A and Granillo, Alejandro and Pouya, Nazanin and Bhimraj, Adarsh and Miller, William R and Tam, Vincent H},
title = {Pharmacokinetics of cefiderocol in a patient with carbapenem‐resistant Acinetobacter baumannii ventriculitis: A case report},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2025},
volume = {45},
number = {1},
pages = {66--69},
doi = {10.1002/phar.4632}
}
EUVIMED